Allan T. Van Oosterom

Allan T. Van Oosterom's AcademicInfluence.com Rankings

Philosophy

#9032

World Rank

#12525

Historical Rank

Logic

#6034

World Rank

#7511

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Allan T. Van Oosterom's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Allan T. Van Oosterom Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Allan T. Van Oosterom's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

New Guidelines to Evaluate the Response to Treatment in Solid Tumors. (2000) (11951)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. (2000) (8707)
Vascular Endothelial Growth Factor and Angiogenesis (2004) (1785)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. (2006) (836)
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) (773)
Soft tissue sarcomas of adults: state of the translational science. (2003) (559)
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). (2003) (544)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer (2001) (520)
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (1999) (512)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. (2005) (484)
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. (2006) (465)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. (2004) (449)
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. (2005) (427)
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. (1998) (425)
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. (2005) (413)
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. (2010) (334)
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. (2001) (324)
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 (2003) (315)
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). (2006) (301)
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. (1992) (289)
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. (1997) (288)
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. (2005) (285)
Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate (2006) (267)
cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). (1987) (248)
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (234)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity (2004) (210)
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. (2006) (208)
Prognostic value of bcl-2 expression in invasive breast cancer. (1995) (195)
Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases (2008) (177)
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. (2003) (173)
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. (2002) (165)
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. (1999) (157)
A phase II trial with rosiglitazone in liposarcoma patients (2003) (152)
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. (1996) (148)
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2000) (147)
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. (1987) (136)
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? (1999) (129)
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. (1995) (127)
Oxidative DNA Damage: Biological Significance and Methods of Analysis (2002) (122)
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group (1984) (120)
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. (1989) (118)
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (115)
Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. (1987) (110)
Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. (1995) (108)
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. (1991) (105)
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). (2006) (99)
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. (1990) (98)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. (2003) (98)
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. (2007) (98)
Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). (2005) (93)
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. (1998) (91)
Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. (1995) (90)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. (1993) (90)
Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. (2004) (88)
In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. (2001) (88)
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. (2006) (87)
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. (1999) (86)
Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors (2005) (85)
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA (1997) (84)
Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study. (1995) (81)
Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. (2005) (78)
Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines (2006) (77)
cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. (1988) (77)
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. (1984) (76)
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. (1995) (73)
Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation (1988) (72)
Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. (1986) (71)
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. (1987) (69)
Coping with toxicities of docetaxel (Taxotere). (1993) (69)
Role of red blood cells in pharmacokinetics of chemotherapeutic agents. (1999) (68)
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. (2000) (66)
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. (1995) (64)
Tumor lysis syndrome in a patient with metastatic merkel cell carcinoma (1991) (54)
Five‐year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin (1984) (54)
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors (2010) (53)
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. (1998) (53)
Nanotechnology in bio/clinical analysis. (2000) (52)
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. (2004) (52)
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. (1995) (51)
Gastrointestinal stromal tumor of the prostate. (2005) (51)
Long-term results of continuous treatment with recombinant interferon-a in patients with metastatic carcinoid tumors—an antiangiogenic effect? (1996) (50)
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. (1986) (49)
Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. (1983) (48)
Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. (1996) (48)
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. (1998) (47)
Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. (2003) (46)
P-glycoprotein: clinical significance and methods of analysis. (1995) (45)
EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials. (1991) (45)
Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. (2006) (44)
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. (1993) (44)
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours (2004) (43)
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. (2001) (42)
Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma (2004) (42)
Alkaline phosphatase isoenzyme patterns in malignant disease. (1992) (42)
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer (2007) (41)
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. (1994) (41)
Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies (2005) (40)
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5‐HT3 receptor antagonist, with a metoclopramide‐containing antiemetic cocktail in the prevention of cisplatin‐induced emesis (1994) (40)
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. (2008) (40)
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. (1994) (39)
Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. (1996) (38)
Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times (1992) (38)
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. (1995) (38)
Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1985) (38)
Flow cytometric double labeling technique for screening of multidrug resistance. (1991) (37)
STI571: a magic bullet? (2001) (35)
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results? (1993) (35)
Determination of the underivatized antineoplastic drugs cyclophosphamide and 5-fluorouracil and some of their metabolites by capillary gas chromatography combined with electron-capture and nitrogen-phosphorus selective detection. (1983) (35)
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study (2004) (35)
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) (2005) (35)
Detection of Micrometastatic Disease and Monitoring of Perioperative Tumor Cell Dissemination in Primary Operable Breast Cancer Patients Using Real-Time Quantitative Reverse Transcription-PCR (2004) (35)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) (2000) (34)
Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. (1986) (34)
Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. (1997) (34)
Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. (1991) (34)
Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. (1985) (34)
In vitro toxicity studies with mitomycins and bleomycin on endothelial cells (1997) (33)
Activated oxazaphosphorines are transported predominantly by erythrocytes. (1997) (33)
CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. (1983) (31)
EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents. (1991) (30)
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. (1997) (30)
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. (2005) (30)
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man (2001) (28)
Radiation therapy for in situ or localized breast cancer. (1993) (27)
Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1990) (26)
Partitioning of ifosfamide and its metabolites between red blood cells and plasma. (1996) (26)
Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients (2006) (26)
DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). (2006) (26)
The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. (1994) (26)
Determination of mitomycin C in plasma, serum and urine by high-performance liquid chromatography with ultra-violet and electrochemical detection. (1982) (25)
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? (1987) (25)
Interferon‐α‐2a with or without 13‐cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma (2004) (25)
Phase II Study of Plitidepsin 3-Hour Infusion Every 2 Weeks in Patients With Unresectable Advanced Medullary Thyroid Carcinoma (2010) (25)
Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC (2008) (25)
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. (1994) (25)
Diagnosis and treatment of soft tissue sarcomas in adults. (1994) (24)
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study (2007) (24)
Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study. (1982) (23)
E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. (1979) (23)
Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum. (1995) (23)
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. (2004) (23)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. (1990) (22)
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1997) (22)
EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. (1997) (22)
Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. (2000) (21)
Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. (1999) (21)
Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. (1992) (21)
Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry. (2002) (20)
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. (2006) (20)
Soft tissue sarcoma in adults. (1993) (20)
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma (2008) (20)
Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. (1995) (20)
Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. (2007) (19)
Altered irinotecan metabolism in a patient receiving phenytoin. (2002) (19)
Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. (1997) (19)
An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. (1997) (18)
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. (1998) (18)
Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. (1995) (18)
Irinotecan in cancers of the lung and cervix. (1999) (18)
Late peritoneal metastasis in a patient with osteosarcoma. (1998) (18)
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. (1998) (18)
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. (2001) (17)
Primary extrauterine müllerian adenosarcoma of the peritoneum. (1995) (17)
A gas chromatographic assay for the determination of 5,6-dihydrofluorouracil and 5-fluorouracil in human plasma. (1983) (16)
Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. (1986) (16)
Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study. (1983) (16)
Variations in exposure to mitomycin C in an in vitro colony-forming assay. (1986) (16)
Multidrug Resistance in Rat Colon Carcinoma Cell Lines CC531, CC531mdr+ and CC531rev (1993) (15)
Pharmacokinetics of the cytostatic drugs used in the CMF-regimen. (1983) (15)
Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1985) (15)
New drugs for the treatment of sarcomas. (1995) (15)
In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender (2005) (14)
Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques. (1988) (14)
Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 (2012) (14)
In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation. (2006) (13)
Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. (1997) (13)
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry. (2005) (13)
Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. (2006) (13)
Melphalan availability in hypoxia‐inducible factor‐1α+/+ and factor‐1α–/– tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport (2002) (13)
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. (1992) (13)
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group. (1985) (12)
Benign fibrous histiocytoma of the larynx: presentation of a case and review of the literature (1996) (12)
Proteomics in cancer research: methods and application of array-based protein profiling technologies. (2006) (12)
Cisplatin‐DNA adducts and protein‐bound platinum in blood of testicular cancer patients (1998) (12)
In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking (2005) (12)
Combined modality treatment of short duration in small cell lung cancer. (1984) (12)
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study. (1987) (12)
Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns. (1994) (11)
N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group. (1982) (11)
Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometry. (1987) (11)
Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1984) (11)
Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome. (2001) (11)
Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. (2006) (11)
Bioanalysis of suramin in human plasma by ion-pair high-performance liquid chromatography. (1990) (10)
Phase II study of elliptinium in metastatic soft tissue sarcoma. (1985) (10)
Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. (1999) (10)
The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment (2004) (10)
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (1993) (10)
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) (1991) (10)
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study (2000) (9)
Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. (1996) (9)
KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. (1999) (9)
Determination of plasma concentrations of underivatized cyclophosphamide by capillary gas chromatography. (1981) (9)
The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. (1999) (9)
Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies (2002) (9)
Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group. (1987) (8)
Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). (2016) (8)
Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group. (1984) (8)
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. (1984) (8)
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group. (1982) (8)
Neoadjuvant and adjuvant therapy for invasive bladder tumors. (1991) (8)
Chondrosarcoma and other rare bone sarcomas. (1990) (8)
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer. (1988) (8)
Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group. (1986) (7)
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. (2003) (7)
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases. (1991) (7)
Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. (2004) (7)
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors (2004) (7)
Predictive testing in cancer chemotherapy. I. In vivo. (1985) (6)
Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
Intraperitoneal chemotherapy in ovarian carcinoma. (1987) (6)
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (6)
The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
EORTC Genito-Urinary Group studies in advanced testicular cancer--past and future. (1985) (6)
5′‐Deoxy‐S‐fluorouridine Increases Daunorubicin Uptake in Multidrug‐resistant Cells and Its Activity Is Related with P‐gp 170 Expression (1994) (6)
Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group. (1983) (5)
Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer. (2004) (5)
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. (1998) (5)
A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1989) (5)
Is there an increased risk for tumor dissemination using ultrasonic surgical aspiration in patients with vulvar carcinoma? (1994) (5)
The role of ifosfamide in the treatment of sarcomas. (1989) (5)
Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer. (1988) (5)
A comparison of two culture techniques: an in vitro & an in vivo tumour colony-forming assay. (1985) (5)
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer. (1986) (5)
High endothelial cell proliferation index and high microvessel density in vascular hotspots suggest an active angiogenic process in human colorectal adenocarcinomas. Angiogenesis Group. (1996) (5)
5‐Fluorouracil/leucovorin/interferon alpha‐2a in patients with advanced colorectal cancer (1995) (4)
Cryptorchidism and extragonadal germ cell tumor. (1995) (4)
Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. (2004) (4)
Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C. (1991) (4)
Differential protein expression profile in gastrointestinal stromal tumors (2004) (4)
Simultaneous determination of the peptide-mitomycin KW-2149 and its metabolites in plasma by high-performance liquid chromatography. (2000) (4)
The influence of ethanol on cyclophosphamide pharmacokinetics and metabolism in tumor-bearing rats. (1987) (4)
Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. (2006) (4)
Angiogenesis: possibilities for therapeutic interventions (1998) (3)
The human tumour colony-forming assay using fresh specimens. (1986) (3)
Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. (1995) (3)
A Sarcoma at the Site of Previous Extravasation of Adriamycin (2002) (3)
Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder. (1984) (3)
The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract. (1994) (2)
Disseminated lung cancer or extragonadal germ cell tumour? (1991) (2)
Plasma levels during intravesical instillation of mitomycin-C. (1985) (2)
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells. (1997) (2)
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. (1990) (2)
Chondrosarcoma and other rare bone sarcomas. (1990) (2)
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies. (1999) (2)
Microvascular count and prognosis in colorectal cancer. (1996) (2)
[In vitro effects of piracetam on the radiosensitivity of hypoxic cells (adaptation of MTT assay to hypoxic conditions)]. (1995) (2)
Alpha-interferon (IFN) in the treatment of metastatic carcinoid tumors. (1991) (1)
Neoadjuvant/primary chemotherapy in cancer treatment: what advantage? (1999) (1)
Late relapse of a non-seminomatous germ cell tumour from residual mature teratoma. (1998) (1)
Superior vena cava syndrome as the presenting symptom of an endoluminal metastasis of an osteosarcoma. (1990) (1)
Botryomycosis mimicking a liposarcoma. (1997) (1)
Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1989) (1)
Administration of 24-hour intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps. (2009) (1)
4'Deoxydoxorubicin in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1986) (1)
Diagnosis and treatment of soft tissue sarcomas in adults. (1995) (1)
Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model. (2003) (1)
Allan van Oosterom, President of the EORTC. European Organisation for the Research and Treatment of Cancer. Interview by Jeroen van der Boon. (2002) (0)
[Cured of testicular cancer; does life just go on?]. (1990) (0)
TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. (1989) (0)
Intrahepatic mitomycin C as treatment of breast cancer hepatic metastasis. (2016) (0)
The multidisciplinary approach to treatment of soft tissue sarcomas. (1992) (0)
Foreword: ET‐743: a novel marine‐derived anti‐tumor agent: Proceedings of an ECCO Satellite Symposium held in Lisbon, October 2001 (2002) (0)
Potential advances in combination chemotherapy for advanced testicular cancer. (1988) (0)
[Interactions of carboplatin, cisplatin, and ionizing radiation on a human cell line of ovarian cancer]. (1999) (0)
The management of ovarian cancer. (1993) (0)
Letters to the editor (0)
Diagnosis and treatment of soft tissue sarcomas in adults. (1996) (0)
The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts. (1996) (0)
Soft tissue sarcoma in adults. (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Allan T. Van Oosterom?

Allan T. Van Oosterom is affiliated with the following schools:

Aarhus University